Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
August 2018
-
Media ReleaseNovartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episodeTRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1…
-
Key ReleaseSOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutationSOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase…
-
Key ReleaseNovartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance OfficerBasel, 14. August 2018 - Novartis hat heute die Ernennung von Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer bekanntgegeben. Er wird an Vas Narasimhan, M.D., den CEO von…
-
Key ReleaseNovartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance OfficerBasel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and…
July 2018
-
Media ReleaseNovartis marks a new era for migraine patients with the EU approval of Aimovig®, a first-of-its-kind treatment specifically designed for migraine preventionPatients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; safety and…
-
Media ReleaseSandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)Biosimilar Hyrimoz® (adalimumab) approved for use in all same indications as reference medicine*** including rheumatology, gastroenterology and dermatology Early therapeutic intervention is…
-
Media ReleaseNovartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanomaPhase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo[1] Relapse-free survival benefit with…
-
Media ReleaseNovartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver flukeNovartis extends agreement with the WHO for the donation of Egaten® for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 million…
-
Media ReleaseNovartis demonstrates commitment to lead immuno-dermatology by in-licensing IL-17C compound for atopic dermatitisNovartis enters an exclusive license agreement with Galapagos and MorphoSys for an investigational biologic compound, MOR106, a novel antibody directed against IL-17C IL-17C is believed to…
-
Media ReleaseNovartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal womenKisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer…
-
Key ReleaseNovartis delivers solid growth in second quarter and continues transformation to a focused medicines companyNet sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…
-
Key ReleaseNovartis réalise une solide croissance au deuxième trimestre et poursuit sa transformation en une entreprise axée sur les médicamentsHausse du chiffre d'affaires net de 5% (tcc[1], +7% USD), stimulée principalement par: Cosentyx, qui a progressé à USD 701 millions, (+40% tcc), enregistrant une forte croissance dans toutes ses…
Pagination
- ‹ Previous page
- 1
- …
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- …
- 100
- › Next page